Pharmacotherapy for exercise-induced asthma: Allowing normal levels of activity and sport

Expert Review of Clinical Pharmacology

Volumn 3, Issue 1, 2010, Pages 139-152

  Fitch, Kenneth D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

2 adrenoceptor agonist; Asthma; Exercise induced bronchoconstriction; Glucocorticosteroid; Pharmacotherapy; Physical activity; Sport

Indexed keywords

BAMBUTEROL; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHROMONE DERIVATIVE; CICLESONIDE; CINALUKAST; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FENOTEROL; FLUNISOLIDE; FLUTICASONE PROPIONATE; FORMOTEROL; FORMOTEROL FUMARATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MOMETASONE FUROATE; MONTELUKAST; MUSCARINIC RECEPTOR BLOCKING AGENT; NEDOCROMIL; PIRBUTEROL ACETATE; PLACEBO; PREDNISONE; RIMITEROL; SALBUTAMOL SULFATE; SALMETEROL; SALMETEROL XINAFOATE; TERBUTALINE SULFATE; THEOPHYLLINE; UNINDEXED DRUG; ZAFIRLUKAST;

BRONCHODILATATION; BRONCHOSPASM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; EVENING DOSAGE; EXERCISE INDUCED ASTHMA; HUMAN; MORNING DOSAGE; PHYSICAL ACTIVITY; REVIEW; SINGLE DRUG DOSE; SPORT; SYSTEMIC DISEASE;

EID: 77949760896     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.52     Document Type: Review

References (203)

1. Areteus of Cappadocia. The Extant Works of Areteus, the Cappadocium. Francis Adams (Ed.). Sydenham Society, London, UK 316 (1856).
2. Major RH. A note on the history of asthma. In: Science, Medicine and History (Volume 2). Underwood EA (Ed.). Oxford University Press, London, UK 522 (1953).
3. Anderson SD, Daviskas E. The mechanism of exercise-induced asthma is' J. Allergy Clin. Immunol. 106(3), 453-459 (2000).
4. Scherr MS, Frankel L. Physical conditioning for asthmatic children. JAMA 168(15), 1996-2000 (1958).
5. Fitch KD, Morton AR, Blanksby BA. Effects of swimming training on children with asthma. Arch. Dis. Child. 51(3), 190-194 (1976).
6. Fitch KD. b2-agonists at the Olympic Games. Clin. Rev. Allergy Immunol. 31(2-3), 259-268 (2006).
7. Langdeau JB, Boulet LP. Prevalence and mechanisms of asthma and airway hyperesponsiveness in athletes. Sports Med. 31(8), 601-616 (2001).
8. Strauss RH, McFadden ER, Ingram RH, Deal SF. Influence of heat and humidity on airway obstruction by exercise in asthma. J. Clin. Invest. 61(2), 433-440 (1978).
9. Anderson SD, Daviskas E, Schoeffel RE, Unger SF. Prevention of severe exerciseinduced asthma with hot humid air. Lancet 2(8143), 629 (1979).
10. Anderson SD, Kippelen P. Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes J. Allergy Clin. Immunol. 122(2), 225-235 (2008).
11. Dahlén SE, Kumlin M. Monitoring mast cell activation by prostaglandin D2 in vivo. Thorax 59(6), 453-455 (2004).
12. Gulliksson M, Palmberg L, Nilsson G, Ahlstedt S, Kumlin M. Release of prostaglandin D2 and leukotrine C in response to hypermolar stimulation of mast cells. Allergy 61(12), 1473-1479 (2006).
13. Lee TH, Brown MJ, Nagy L, Causon R, Walport MJ, Kay AB. Exercise-induced release of histamine and neutrophil chemotactic factor in atopic asthmatics. J. Allergy Clin. Immunol. 70(2), 73-81 (1982).
14. Roca J, Whipp BJ, Augusti AGN et al. Clinical exercise testing with reference to lung diseases: indications, standardization, interpretation strategies. Position statement of the European Respiratory Society. Eur. Respir. J. 10(11), 2662-2689 (1997).
15. Crapo RO, Casaburi R, Coates AL et al. Guidelines for methacholine and exercise challenge testing - 1999. Official statement of the American Thoracic Society. Am. J. Respir. Crit. Care Med. 161(1), 309-329 (2000).
16. Rundell KW, Slee JB. Exercise and other indirect challenges to demonstrate asthma or exercise-induced bronchoconstriction in athletes. J. Allergy Clin. Immunol. 122(2), 238-246 (2008).
17. Anderson SD, Fitch K, Perry CP et al. Responses to bronchial challenge submitted for approval to use inhaled b2-agonists before an event at the 2002 Winter Olympics. J. Allergy Clin. Immunol. 111(1), 45-50 (2003).
18. Bernard A, Carbonelle S, Michel O et al. Lung hyperpermeability and asthma prevalence in schoolchildren; unexpected associations with the attendance at indoor chlorinated swimming pools. Occup. Environ. Med. 60, 385-394 (2003)
19. Brunekreef B, Hoek G,Breugelmans O, Leentvaar M. Respiratory effects of low-level photochemical air pollution in amateur cyclists. Am. J. Respir. Crit. Care Med. 150(4), 962-966 (1994).
20. Kehrl HR, Roger LJ, Hazucha MJ, Horstman DH. Differing response of asthmatics to sulfur dioxide exposure with continuous and intermittent exercise. Am. Rev. Respir. Dis. 135(2), 350-355 (1987).
21. Roger LJ, Horstman DH, McDonnell W et al. Pulmonary function, airway responsiveness and respiratory symptoms in asthmatics following exercise in NO2. Toxicol. Ind. Health 6(1), 155-171 (1990).
22. McCreanor J, Cullinan P, Niewenhuijsen MJ et al. Respiratory effects of exposure to diesel traffic in persons with asthma. N. Engl. J. Med. 357(23), 2348-2358 (2007).
23. Larsson K, Ohlsén P, Larsson L, Malmberg P, Rydström PO. High prevalence of asthma in cross-country skiers. Br. Med. J. 307(6915), 1326-1329 (1993).
24. Karjalainen EM, Laitinen A, Sue-Chu M, Altraja A, Bjermer L, Laitinen LA. Evidence of airway inflammation and remodelling in ski athletes with and without bronchial hyperresponsiveness to methacholine. Am. J. Respir. Crit. Care Med. 161(6), 2086-2091 (2000).
25. Moore K, Neugebauer R, Lurmann F et al. Ambient ozone concentrations cause increased hospitalizations for asthma in children: an 18-year study in Southern California. Environ. Health Perspect. 116(8), 1063-1070 (2008).
26. Rundell KW. Pulmonary function decay in ice hockey players: is there a relationship to ice rink air quality? Inhal. Toxicol. 17(3), 117-123 (2004)
27. Fitch KD, Morton AR. Specificity of exercise in exercise-induced asthma. Br. Med. J. 4(5787), 577-581 (1971).
28. Mustchin CP, Pickering CA. "Coughing water"; bronchial hyperreactivity following swimming in a chlorinated pool. Thorax 34(5), 682-683 (1979).
29. Weisel CP, Richardson SD, Nemery B et al. Childhood asthma and environmental exposures at swimming pools; state of the science and research recommendations. Environ. Health Perspect. 117(4), 500-507 (2009).
30. Åstrand P-O, Rodahl K. Textbook of work physiology. McGraw Hill Book Company, NY, USA, 389-408(1970).
31. Carlsen KH, Engh G, Mørk M. Exerciseinduced bronchoconstriction depends on exercise load. Respir. Med. 94(4), 750-755 (2000).
32. Henriksen JM, Nielsen TT. Effect of physical training on exercise-induced bronchoconstriction. Acta Paediatr. Scand. 72(1), 31-36 (1983).
33. Reiff DB, Choudry NB, Pride NB, Ind PW. The effect of prolonged submaximal warm-up exercise on exercise-induced asthma. Am. Rev. Respir. Dis. 139(2), 479-484 (1989).
34. McKenzie DC, McLuckie SL, Stirling DR. The protective effects of continuous and interval exercise in athletes with exerciseinduced asthma. Med. Sci. Sports Exerc. 26(8), 951-956 (1994).
35. de Bisschop C, Guenard H, Desnot P, Vergeret J. Reduction of exercise-induced asthma in children by short repeated warm ups. Br. J. Sports Med. 33(2), 100-104 (1999).
36. Mickleborough TD, Lindley MR, Turner LA. Comparative effects of a high intensity interval warm-up and salbutamol on the bronchoconstrictor response to exercise in asthmatic athletes. Int. J. Sports Med. 28(6), 456-462 (2007).
37. Manning PJ, Watson RM, O'Byrne PM. Exercise-induced refractoriness in asthmatic subjects involves leukotriene and prostaglandin independent mechanisms. Am. Rev. Respir. Dis. 148(4 Pt 1), 950-954 (1993).
38. Nowak D, Jörres R, Magnussen H. Influence of exercise-induced bronchoconstriction on refractoriness. Lung 170(2), 75-84 (1992).
39. Brenner AM, Weisner PC, Krogh LA, Loren ML. Effectiveness of a portable face mask in attenuating exercise-induced asthma. JAMA 244 (19), 2196-2198 (1980).
40. Millqvist E, Bake B, Bengtsson U, Löwhagen O. Prevention of asthma induced by cold air by cellulose-fabric mask. Allergy 50(3), 221-224 (1995).
41. Nisar M, Spence DP, West D et al. A mask to modify inspired air temperature and humidity and its effect on exercise induced asthma. Thorax 47, 446-450 (1992).
42. Beuther DA, Martin RJ. Efficacy of a heat exchanger mask in cold exercise-induced asthma. Chest 129(5), 1188-1193 (2006).
43. Cullum VA, Farmer JB, Jack D, Levy GP. Salbutamol: a new selective b-adrenoceptive receptor stimulant. Br. J. Pharmacol. 35(1), 141-151 (1969).
44. Tattersfield AE. Current issues with b-2 adrenoceptor agonists: historical background. Clin. Rev. Allergy Immunol. 31(2-3), 107-117 (2006).
45. Anderson SD, Caillaud C, Brannan JD. b-2 agonists and exercise-induced asthma. Clin. Rev. Allergy Immunol. 31(2-3), 163-180 (2006).
46. Anderson SD, Seale JP, Rozea P, Bandler L, Theobald G, Lindsay DA. Inhaled and oral salbutamol in exerciseinduced asthma. Am Rev. Respir. Dis. 114(3), 493-500 (1976).
47. Godfrey S, König P. Inhibition of exercise-induced asthma by different pharmacological pathways. Thorax 31(2), 137-142 (1976).
48. Sly RM, Puapan P, Ghazanshahi S, Midha R. Exercise-induced bronchospasm: evaluation of albuterol aerosol. Ann. Allergy 34(1), 7-14 (1975).
49. Hills EA, Davies S, Geary M. Salmefamol and salbutamol in exercise-induced asthma in children. Br. J. Dis. Chest 70(2), 78-82 (1976).
50. Higgs CM, Laszlo G. The duration of protection from exercise-induced asthma by inhaled salbutamol and a comparison with reproterol. Br. J. Dis. Chest 77(3), 262-269 (1983).
51. Bronsky EA, Spector SL, Pearlman DS, Justus SE, Bishop AL. Albuterol aerosol versus albuterol Rotacaps in exerciseinduced bronchospasm in children. J. Asthma 32(3), 207-214 (1995).
52. Anderson SD, Lambert S, Brannan JD et al. Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices. Med. Sci. Sports Exerc. 33(6), 893-900 (2001).
53. Hawkesworth RJ, Sykes AP, Faris M, Mant T, Lee TH. Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction. Ann. Allergy Asthma Immunol. 88(5), 473-477 (2002).
54. Brittain RT, Farmer JB, Marshall RJ. Some observations on the b-adrenoceptor agonist properties of the isomers of salbutamol. Br. J. Pharmacol. 48(1), 144-147 (1973).
55. Slattery D, Wong SW, Colin AA. Levalbuterol hydrochloride. Pediatr. Pulmonol. 33(2), 151-157 (2002).
56. Pearlman DS, Rees W, Schaefer K, Huang H, Andrews WT. An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm. J. Asthma 44(9), 729-733 (2007).
57. Morse JL, Jones NL, Anderson GD. The effect of terbutaline in exercise-induced asthma. Am. Rev. Respir. Dis. 113(1), 89-92 (1976).
58. dos Santos JM, Costa H, Ståhl E, Wiren JE. Bricanyl Turbuhaler and Ventolin Rotahaler in exercise-induced asthma. Allergy 46(3), 203-205 (1991).
59. Vilsvik J, Schaanning J, Ståhl E, Holthe S. Comparison between Bricanyl Turbuhaler and Ventolin metered dose inhaler in the treatment of exercise-induced asthma. Ann. Allergy 67(3), 315-318 (1991).
60. Svenonius E, Arborelius M, Wiberg R, Ståhl E, Svensson M. A comparison of terbutaline inhaled by Turbuhaler and by a chlorofluorocarbon (CFC) inhaler in children with exercise-induced asthma. Allergy 49(6), 408-412 (1994).
61. Rabe KF, Jörres R, Magnussen H. The effect of 10, 50 and 200 micrograms inhaled fenoterol on exercise induced asthma. Clin. Exp. Allergy 23(5), 440-445 (1993).
62. Morton AR, Scott CA, Fitch KD. Rimiterol and the prevention of exerciseinduced asthma. J. Allergy Clin. Immunol. 83(1), 61-65 (1989).
63. Aebischer JC, Benoit RC, Scherrer M. Pirbuterol and salbutamol aerosol for exercise-induced bronchoconstriction. Schweiz Med. Wochenschr. 114(46), 1660-1664 (1984).
64. Morooka T, Nishima S, Ota S. Prevention of exercise-induced bronchospasm in asthmatic children. Effect of aerosol and oral procaterol hydrochloride. J. Asthma 24(6), 335-346 (1987).
65. Scheoffel RE, Anderson SD, Seale JP. The protective effect and duration of action of metaproterenol aerosol on exercise-induced asthma. Ann. Allergy 46(5), 273-275 (1981).
66. Anderson SD. Single-dose agents in the prevention of exercise-induced asthma: a descriptive review. Treat. Respir. Med. 3(6), 365-379 (2004).
67. Johnson M. The b-adrenoceptor. Am. J. Respir. Crit. Care Med. 158(5 Pt 3), S146-S153 (1998).
68. Ullman A, Svedmyr N. Salmeterol, a new long acting b-2 adrenoceptor agonist; comparison with salbutamol in adult asthmatic patients. Thorax 43(9), 674-678 (1988).
69. Anderson SD, Rodwell LT, Du Toit J, Young IH. Duration of protection by inhaled salmeterol in exercise-induced asthma. Chest 100(5), 1254-1260 (1991).
70. Newnham DM, Ingram CG, Earnshaw J, Palmer JB, Dhillon DP. Salmeterol provides prolonged protection against exerciseinduced bronchoconstriction in a majority of subjects with mild, stable asthma. Respir. Med. 87(6), 439-444 (1993).
71. Sichletidis L, Daskalopoulou E, Kyriazis G et al. Comparative efficacy of salbutamol and salmeterol in exercise-induced asthma. J. Int. Med. Res. 21(2), 81-88 (1993).
72. Schaanning J, Vilsvik J, Henriksen AH, Bratten G. Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction. Ann. Allergy Asthma Immunol. 76(1), 57-60 (1996).
73. McAlpine LG, Thomson NC. Prophylaxis of exercise-induced asthma with inhaled formoterol, a long acting b-2 adrenergic agonist. Respir. Med. 84(4), 293-295 (1990).
74. Richter K, Jamicki S, Jörres RA, Magnussen H. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur. Respir. J. 19(5), 865-871 (2002).
75. Boner AL, Spexia E, Piovesan P, Chiocca E, Maiocchi G. Inhaled formoterol in the prevention of exerciseinduced bronchoconstriction in asthmatic children. Am. J. Respir. Crit. Care Med. 149(4 Pt 1), 935-939 (1994).
76. Shapiro GS, Yegen U, Xiang J, Kottakis J, Della Cioppa G. A randomized, double blind, single crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol. Clin. Ther. 24(12), 2077-2087 (2002).
77. Pearlman D, Milgrom H, Till D, Ziehmer B. Effect of formoterol fumarate treatment on exercise-induced bronchoconstriction in children. Ann. Allergy Asthma Immunol. 97(3), 382-388 (2006).
78. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exerciseinduced bronchoconstriction. Am. J. Respir. Crit. Care Med. 153(1), 65-69 (1996).
79. Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD. b2-agonist tolerance and exercise-induced bronchospasm. Am.J. Crit Care Med. 165(8), 1068-1070 (2002).
80. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise-induced bronchoconstriction after chronic dosing with salmeterol. Respir. Med. 88(5), 363-368 (1994).
81. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exerciseinduced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 99(5), 655-659 (1997).
82. Haney S, Hancox RJ. Overcoming b-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled studies. Respir. Res. 8(1), 19 (2007).
83. Fitch KD, Sue-Chu M, Anderson SD et al. Asthma and the elite athlete: Summary of the International Olympic Committee's Consensus Conference Lausanne Switzerland, January 22-24, 2008. J. Allergy Clin. Immunol. 122(2), 254-260 (2008).
84. Weinberger M. Long-acting b-agonists and exercise. J. Allergy Clin. Immunol. 122(2), 251-253 (2008).
85. Haney S, Hancox RJ. Tolerance to bronchodilation during treatment with long acting b-agonists, a randomised controlled trial. Respir. Res. 6(1), 107 (2005).
86. Davis BE, Reid JK, Cockcroft DW. Formoterol thrice weekly does not result in the development of tolerance to bronchoprotection. Can. Respir. J. 10(1), 23-26 (2003).
87. Haney S, Hancox RJ. Rapid onset of tolerance to b-agonist bronchodilation. Respir. Med. 99(5), 566-571 (2005).
88. Taylor DR. The b-agonist saga and its clinical relevance: on and on it goes. Am. J. Resp. Crit. Care Med. 179(11), 976-978 (2009).
89. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129(1), 15-26 (2006).
90. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long acting b-agonists on severe asthma exacerbations and asthma-related deaths. Ann. Intern. Med. 144(12), 904-912 (2006).
91. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst. Rev. 16(3), CD006363 (2008).
92. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst. Rev. 4, CD006923 (2008).
93. Wijesinghe M, Perrin K, Harwood M, Weatherall M, Beasley R. The risk of asthma mortality with inhaled long acting b-agonists. Postgrad. Med. J. 84(995), 467-472 (2008).
94. Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodrigues JA. Safety of regular use of long acting b agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm. Pharmacol. Ther. 22(1), 9-19 (2009).
95. Cazzola M, Matera MG. Safety of long acting b-2 agonists in the treatment of asthma. Ther. Adv. Respir. Dis. 1(1), 35-46 (2007).
96. Koh MS, Irving LB. Evidence-based pharmacologic treatment for mild asthma. Int. J. Clin. Pract. 61(8), 1375-1379 (2007).
97. Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir. Med. 100(8), 1297-1306 (2006).
98. Cole TJ, Mollard R. Selective glucocorticoid receptor ligands. Med. Chem. 3(5), 494-506 (2007).
99. König P, Jaffe P, Godfrey S. Effect of corticosteroids on exercise-induced asthma provoked by treadmill running. J. Allergy Clin. Immunol. 54(1), 14-19 (1974).
100. Freezer NJ, Croasdell H, Doull IJM, Holgate ST. Effect of regular inhaled beclomethasone on exercise and methacholine responses in school children with recurrent wheeze. Eur. Resp. J. 8(9), 1488-1493 (1995).
101. Seale JP, Harrison LI. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir. Med. 92(Suppl. A) 9-15 (1998).
102. Petersen R, Agertoft L, Pedersen S Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma. Eur. Respir. J. 24(6), 932-937 (2004).
103. Hendriksen JM, Dahl R. Effects of inhaled budesonide alone and in combination with low dose terbutaline in children with exercise-induced asthma. Am. Rev. Respir. Dis. 128, 993-997 (1983).
104. Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE. Effect of inhaled budesonide on bronchial reactivity to histamine, exercise and eucapnic dry air hyperventilation in patients with asthma. Thorax 46(11), 811-816 (1991).
105. Jónasson G, Carlsen KH, Hultqvist P. Low-dose budesonide improves exerciseinduced bronchospasm in schoolchildren. Pediatr. Allergy Immunol. 11(5), 120-125 (2000).
106. Thio BJ, Slingerland GL, Nagelkerke AF, Roord JJ, Dankert-Roelse JE. Effects of single dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study. Pediatr. Pulmonol. 32(2), 115-121 (2001).
107. Hofstra WB, Neijens HJ, Duiverman EJ et al. Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma. Pediatr. Pulmonol. 29(6), 415-423 (2000).
108. Christie P. Ciclesonide: a novel inhaled corticosteroid for asthma. Drugs Today (Barc.) 40(7), 569-576 (2004).
109. Deeks ED, Perry CM. Ciclesonide: a review of its use in the management of asthma. Drugs 68(12), 1741-1770 (2008).
110. Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus other inhaled steroids from chronic asthma in children and adults. Cochrane Database Syst Rev. 16(2), CD007031 (2008).
111. Subbarao P, Doung M, Adelroth E et al. Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. J. Allergy Clin. Immunol. 117(5), 1008-1013 (2006).
112. Jónassen G, Carlsen KH, Blomqvist P. Clinical efficacy of low dose budesonide once or twice daily in children with mild asthma not previously treated with steroids. Eur. Respir. J. 12(5), 665-671 (1998).
113. Hartley JP, Charles TJ, Seaton A. Betamethasone valerate and exerciseinduced asthma in adults. Br. J. Dis. Chest 71(4), 253-258 (1977).
114. Yazigi R, Sly RM, Frazer M. Effect of triamcinolone acetonide aerosol upon exercise-induced asthma. Ann. Allergy 40(5), 322-325 (1978).
115. Abdullah AK, Khan S. Relative oral corticosteroid-sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis. Ann. Allergy Asthma Immunol. 101(1), 74-81 (2008).
116. Markham A, Faulds D. Montelukast. Drugs 56(2), 251-256 (1998).
117. Kemp JP, Dockhorn RJ, Shapiro GG et al. Montelukast once daily inhibits exerciseinduced bronchoconstriction in 6-14 year-old children with asthma. J. Pediatr. 133(3), 424-428 (1998).
118. Philip G, Villarán C, Pearlman DS, Loevs T, Dass SB, Reiss TF. Protection against exercise-induced bronchocontriction two hours after a single oral dose of montelukast. J. Asthma 44(3), 213-217 (2007).
119. Kim JH, Lee SY, Kim HB, Shim JY, Hong TJ, Hong SJ. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr. Pulmonol. 39(2), 162-166 (2005).
120. Pajaron-Fernandez M, Garcia-Rubia S, Sanchez-Solis M, Garcia-Marcos L. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatr. Pulmonol. 41(3), 222-227 (2006).
121. Mastalerz L, Gawlewicz A, Nizankowska E, Cmiel A, Szczeklik A. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin tolerant patients with asthma. Clin. Exp. Allergy 32(9), 1360-1365 (2002).
122. Leff JA, Busse WW, Pearlman D et al. Montelukast, a leukotriene receptor antagonist for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Eng. J. Med. 339(3), 147-152 (1998).
123. Pearlman DS, van Adelsberg J, Philip G et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single dose of montelukast. Ann. Allergy Asthma Immunol. 97(1), 98-104 (2006).
124. Villaran C, O'Neill SJ, Helbling A et al. Montelukast versus salmeterol in asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol study group. J. Allergy Clin. Immunol. 104(3 Pt 1), 547-553 (1999).
125. Edelman JM, Turpin JA, Bronsky EA et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double blind trial. Exercise study group. Ann. Intern. Med. 132(2), 97-104 (2000).
126. Dahlén B, Roquet A, Inman MD et al. Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. J. Allergy Clin. Immunol. 109(5), 789-793 (2002).
127. Coreno A, Skowronski M, Kotaru C, McFadden ER Jr. Comparative effects of long acting b2 agonists, leukotriene receptor antagonists and a 5-lipoxygenase inhibitor on exercise-induced asthma. J. Allergy Clin. Immunol. 106(3), 500-506 (2000).
128. Adelroth E, Inman MD, Summers E, Pace D, Modi M, O'Byne PM. Prolonged protection against exercise-induced bronchoconstriction by the leuketriene D-4 receptor antagonist cinalukast. J. Allergy Clin. Immunol. 99(2), 210-215 (1997).
129. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchoconstriction by zileuton: a 5-lipoxygenase inhibitor. Am. J. Respir. Crit. Care Med. 153(3), 931-935 (1996).
130. Howell JB, Altounyan RE. A double-blind trial of disodium cromoglycate in the treatment of allergic bronchial asthma. Lancet 2(7515), 539-542 (1967).
131. Morton AR, Fitch KD. Sodium cromoglycate BP in the prevention of exercise-induced asthma. Med. J. Aust. 2(5), 158-162 (1974).
132. Dahl R, Henriksen JM. Effect of oral and inhaled sodium cromoglycate in exerciseinduced asthma. Allergy 35(4), 363-365 (1980).
133. Corkey C, Mindorff C, Levison H, Newth C. Comparison of three different preparations of disodium cromoglycate in the prevention of exercise-induced bronchospasm: a double blind study. Am. Rev. Respir. Dis. 125(6), 623-626 (1982).
134. Boner AL, Niero E, Grigolini C, Valletta EA, Biancotto R, Gaburro D. Inhibition of exercise-induced asthma by three forms of sodium cromoglycate. Eur. J. Respir. Dis. 66(1), 21-24 (1985).
135. Jones DT, Flannery EM, Sears MR. Exercise-induced asthma; comparison of cromoglycate powder and aerosol four hours before exercise. N. Z. Med. J. 97(747), 6-8 (1984).
136. Juniper EF, Kline PA, Morris MM, Hargreave FE. Airway constriction by isocapnic hyperventilation of cold, dry air: comparison of magnitude and duration of protection by nedocromil sodium and sodium cromoglycate. Clin. Allergy 17(6), 523-528 (1987).
137. de Benedictis FM, Tuteri G, Pazzelli P, Bertotto A, Bruni L, Vaccaro R. Cromolyn versus nedocromil; duration of action in exercise-induced asthma in children. J. Allergy Clin. Immunol. 96(4), 510-514 (1995).
138. Chudry N, Correa F, Silverman M. Nedocromil sodium and exercise-induced asthma. Arch. Dis Child. 62(4), 412-414 (1987).
139. Henriksen JM. Effect of nedocromil sodium on exercise-induced bronchoconstriction in children. Allergy 43(6), 449-453 (1988).
140. Cavallo A, Cassaniti C, Glogger A, Magrini H. Action of nedocromil sodium in exercise-induced asthma in adolescents. J. Investig. Allergol. Clin. Immunol. 5(5), 286-288 (1995).
141. König P, Hordvik NL, Kreutz C. The preventive effect and duration of action of nedocromil sodium and cromolyn sodium on exercise-induce asthma (EIA) in adults. J. Allergy Clin. Immunol. 79(1), 64-68 (1987).
142. Oseid S, Mellbye E, Hem E. Effect of nedocromil sodium on exercise-induced bronchoconstriction exacerbated by inhalation of cold air. Scand. J. Med. Sci. Sports 5(2), 88-93 (1995).
143. Todaro A, Faina M. Alippi B, Dal Monte A, Ruggieri F. Nedocromil sodium in the prevention of exerciseinduced bronchospasm in athletes with asthma. J. Sports Med. Phys. Fitness 33(2), 137-145 (1993).
144. Vilsvik J, Schaanning J. A comparative study of the effect of three doses of nedocromil sodium and placebo given by pressurized aerosol to asthmatics with exercise-induced bronchoconstriction. Ann. Allergy 61(5), 367-370 (1988).
145. Morton AR, Ogle SL, Fitch KD. Effects of nedocromil sodium, cromolyn sodium and a placebo in exercise-induced asthma. Ann. Allergy 68(2), 143-148 (1992).
146. Kelly K, Spooner CH, Rowe BH. Nedocromil sodium vs sodium cromoglycate for preventing exerciseinduced bronchoconstriction in asthmatics. Cochrane Database Syst. Rev. (4), CD002731 (2000).
147. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signalling in the pathophysiology of asthma and COPD. Respir. Res. 7(1), 73 (2006).
148. Gross NJ. Anticholinergic agents in asthma and COPD. Eur. J. Pharmacol. 533(1-3), 36-39 (2006).
149. Wolkove N, Kreisman H, Frank H, Gent M. The effect of ipratropium on exercise-induced bronchoconstriction. Ann Allergy 47(5 Pt 1), 311-315 (1981).
150. Boner AL, Vallone G, De Stafano G. Effect of inhaled ipratropium bromide on methacholine and exercise provocation in asthmatic children. Pediatr. Pulmonol. 6(2), 81-85 (1989).
151. Poppius H, Sovijärvi AR, Tammilehto L. Lack of protective effect of high dose ipratropium on bronchoconstriction following exercise with cold air breathing in patients with mild asthma. Eur. J. Respir. Dis. 68(5), 319-325 (1986).
152. Knöpfli BH, Bar-Or O. Vagal activity and airway response to ipratropium bromide before and after exercise in ambient and cold conditions in healthy cross country runners. Clin. J. Sport Med. 9(3), 170-176 (1999).
153. Knöpfli BH, Bar-Or O, Araújo CG. Effect of ipratropium bromide on EIB in children depends on vagal activity. Med. Sci. Sports Exerc. 37(3), 354-359 (2005).
154. Park HW, Yang MS, Park CS et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 64(5), 778-783 (2009).
155. Banner KH, Page CP. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur. Respir J. 8(6), 996-1000 (1995).
156. Ellis EF, Koysooko R, Levy G. Pharmacokinetics of theophylline in children with asthma. Pediatrics 58(4), 542-547 (1976).
157. Leung P, Kalisher A, Bell TD. Variation in theophylline clearance rate with time in chronic childhood asthma. J. Allergy Clin. Immunol. 59(6), 440-444 (1977).
158. Kelly HW, Murphy S. Serum theophylline levels in asthmatic children receiving sustained-release theophylline tablets. Am. J. Hosp. Pharm. 36(12), 1698-1701 (1979).
159. Bierman CW, Shapiro GG, Pierson WE, Cho YW. Exercise induced bronchospasm in asthmatic children as a dose-response model for theophylline. Int. J. Clin. Pharmacol. Biopharm. 16(6), 245-248 (1978).
160. PollockJ, Kiechel F, Cooper D, Weinberger M. Relationship of serum theophylline concentration to inhibition of exercise-induced bronchoconstriction and comparison with cromolyn. Pediatrics 60(6), 840-844 (1977).
161. Magnussen H, Reuss G, Jörres R. Methylxanthines inhibit exercise-induced bronchoconstriction at low serum theophylline concentrations and in a dose-dependent fashion. J. Allergy Clin. Immunol. 81(3), 531-537 (1988).
162. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N. Eng. J. Med. 329(2), 90-95 (1993).
163. Shimizu T, Mochizuki H, Shigeta M, Morikawa A. Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma. Am. J. Respir. Crit. Care Med. 155(1), 170-173 (1997).
164. Pavord ID, Wisniewski A, Tattersfield AE. Inhaled frusemide and exercise induced asthma: evidence of a role for inhibitory prostanoids. Thorax 47(10), 797-800 (1992).
165. Tecklenburg SL, Mickleborough TD, Fly AD, Bai Y, Stager AM. Ascorbic acid supplementation attenuates exercise induced bronchoconstriction in patients with asthma. Respir. Med. 101(8), 1770-1778 (2007).
166. Mickleborough TD, Murray RL, Ionescu AA, Lindley MR. Fish oil supplementation reduced the severity of exercise-induced bronchoconstriction in elite athletes. Am. J. Respir. Crit. Care Med. 168(10), 1181-1189 (2003).
167. Baumann JM, Rundell KW, Evans TM, Levine AM. Effects of cysteine donor supplementation on exercise-induced bronchoconstriction. Med. Sci. Sports Exerc. 37(9), 1468-1473 (2005).
168. Gotshall RW, Mickleborough TD, Cordain L. Dietary salt restriction improves pulmonary function in exerciseinduced asthma. Med. Sci. Sports Exerc. 32(11), 1815-1819 (2000).
169. Manjra AI, Nel H, Maharai B. Effect of desloratadine on allergic rhinitis and exercise-induced bronchoconstriction: a placebo controlled study. J. Asthma 46(2), 156-159 (2009).
170. Crompton GK. Problem with patients have using pressurised aerosol inhalers. Eur. J. Respir. Dis. Suppl. 119, 101-104 (1982).
171. Kamps AW, van Ewijk B, Roorda RJ, Brand PL. Poor inhalation technique, even after inhalation instructions in children with asthma. Pediatr. Pulmonol. 29(1), 39-42 (2000).
172. Melani AS, Zanchetta D, Barbato N et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann. Allergy Asthma Immunol. 93(5), 439-446 (2004).
173. Plaza V, Sanchis J. Medical personnel and patient skill in the use of metered dose inhalers: a multicentre study. CESEA group. Respiration 65(3), 195-198 (1998).
174. Lavorini F, Fontana GA. Targeting drugs to the airways: the role of spacer devices. Expert Opin. Drug Deliv. 6(1), 91-102 (2009).
175. Piérart F, Wildhaber JH, Vrancken I, Devadason SG, Le Souëf PN. Washing plastic spacers with household detergent reduces electrostatic charge and greatly improves delivery. Eur. Respir. J. 13(3), 673-678 (1999).
176. Chew NY, Reddell HK, Bosnic-Anticevich SZ, Chan HK. Effect of mouthpiece washing on aerosol performance of CFC-free Ventolin. J. Asthma 41(7), 721-727 (2004).
177. Virchow JC, Crompton GK, Dal Negro R et al. Importance of inhaler devices in the management of airway disease. Respir. Med. 102(1), 10-19 (2008).
178. Miller DP, Tom G, Rasoulivan L, Chipps B. Patient-reported outcomes among omalizumab and salmeterol/ flutcasone combination therapy. J. Asthma 46(2), 179-185 (2009).
179. Bougault V, Turmel J, Levesque B, Boulet LP. The respiratory health of swimmers. Sports Med. 39(4), 295-312 (2009)
180. Helenius I, Rytila P, Sarna S et al. Effect of continuing or finishing high-level sports on airways inflammation, bronchial hyperresponsiveness and asthma; a five year follow-up study of 42 highly trained swimmers. J. Allergy Clin. Immmunol. 109(6), 962-968 (2002).
181. Anderson SD, Sue-Chu, Perry CP et al. Bronchial challenges in athletes applying to inhale a b2-agonist at the 2004 Summer Olympics. J. Allergy Clin. Immunol. 117(4), 767-773 (2006)
182. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. Lancet 351(9111), 1225-1232 (1998).
183. European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks and use of asthma medication in the European Community Respiratory Health Survey. Eur.
184. Resnick AD, Deal EC Jr, Ingram RH Jr, McFadden ER Jr. A critical assessment of the mechanism by which hyperoxia attenuates exercise-induced asthma. J. Clin. Invest. 64(2), 541-549 (1979).
185. Anderson SD, Schoeffel RE, Follet R, Perry CP, Daviskas E, Kendall M. Sensitivity to heat and water loss at rest and during exercise in asthmatic patients. Eur. J. Respir. Dis. 63(5), 459-471 (1982).
186. Burr ML, Wat D, Evans C et al. Asthma prevalence in 1973, 1988 and 2003. Thorax 61(4), 296-299 (2006).
187. Braman SS. The global burden of asthma. Chest 130(1 Suppl.), 4S-12S (2006).
188. Becker JM, Rogers J, Rossini G, Mirchandani H, D'Alonzo GE Jr. Asthma deaths during sports: report of a 7-year experience. J. Allergy Clin Immunol. 113(2), 264-267 (2004).
189. DiDario AG, Becker JM. Asthma, sports and death. Allergy Asthma Proc. 26(5), 341-344 (2005).
190. Lang DM. Asthma deaths and the athlete. Clin. Rev. Allergy Immunol. 29(2), 125-129 (2005).
191. Robinson DM, Egglestone DM, Hill PM, Rea HH, Richards GN, Robinson SM. Effects of a physical conditioning program on asthmatic patients. N. Z. Med. J. 105(937), 253-256 (1992).
192. Nelson HS, Carr W, Nathan R, Portnoy JM. Update on the safety of long-acting b-agonists with inhaled corticosteroids in the treatment of asthma. Ann. Allergy Asthma Immunol. 102(1), 11-15 (2009).
193. Humbert M, Andersson TL, Buhl R. Budesonide/formoterol maintenance and reliever therapy in the management of moderate to severe asthma. Allergy 63(12), 1567-1580 (2008).
194. Friedman HS, Eid NS, Crespi S, Wilcox TK, Reardon G. Retrospective claims study of fluticasone propionate/ salmeterol fixed combination use as an initial asthma controller therapy in children despite guideline recommendations. Clin. Ther. 31(5), 1056-1063 (2009).
195. Friedman H, WilcoxT, Reardon G, Crespi S, Yawn BP. A retrospective study of the use of fluticasone propionate/salmeterol combination as initial asthma controller therapy in a commercially insured population. Clin. Ther. 30(10), 1908-1917 (2008).
196. Taylor DR, Jayaram L, Asher MI, Epton MJ. "As required" combination therapy with inhaled corticosteroids and long acting b2 agonists for asthma: current evidence and recommendations. N. Z. Med. J. 121(1285), 106-118 (2008).
197. Papi A, Carmori G, Adcock IM, Barnes PJ. Rescue treatments in asthma. More than as needed bronchodilation. Chest 135(6), 1628-1633 (2009).
198. Yang WH, Martinot JB, Pohunek P et al. Tolerability of indacaterol, a novel once daily b2-agonist in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann. Allergy Asthma Immunol. 99(6), 555-561 (2007).
199. Cazzola M, Matera MG. Novel long acting bronchodilators for COPD and asthma. Br. J. Pharmacol. 155(3), 291-299 (2008).
200. Weiss ST, Litonius AA, Lange C et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics 6(5), 311-326 (2006).
201. Carroll CL, Stoltz P, Schramm CM, Zucker AR. b2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma. Chest 135(5), 1186-1192 (2008).
202. Lima JJ, Blake KV, Tantisira KG, Weiss ST. Pharmacogenetics of asthma. Curr. Opin. Pulm. Med. 15(1), 57-62 (2009).
203. Hall IP, Sayers I. Pharmacogenetics and asthma: false hope or new dawn? Eur. Respir. J. 29(6), 1239-1245 (2007).